Digestive Diseases
| Ulcerative colitis
Digestive Diseases
Ulcerative colitis
Comparative efficacy and safety of upadacitinib vs vedolizumab, ustekinumab, and tofacitinib after one-year maintenance therapy for moderately to severely active ulcerative colitis: 3 matching-adjusted indirect comparisons.
book_2
Source:
UEG Week 2023 - Poster session
calendar_today
Published on Medfyle:
November 2023
In this medfyle
There is a growing armamentarium of novel therapeutic options for the treatment of moderately to severely active ulcerative colitis. This study uses matching-adjusted indirect comparisons methodology to compare the efficacy and safety of upadacitinib versus vedolizumab, ustekinumab, or tofacitinib during maintenance treatment. Results suggesting a favourable benefit-risk profile of upadacitinib versus the other therapies.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the UEG Week 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©2023 Infomedica-Medfyle. All rights reserved.
